New MAb by Aalto Bio debuts in UK cell line development market

The Dublin-based Aalto Bio Reagents Ltd., one of the leading providers of HIV antibodies, disease state human plasma, and antigens to the in-vitro diagnostic industry, has apparently announced the availability of its latest mouse monoclonal antibody to the Helicobacter pylori (H. pylori) flagellin. The MAb, say reports, would be made available for researchers, vaccine developers, diagnostic test manufacturers, and numerous other known players of cell line development industry.

For the record, H. pylori is a gram-negative bacterium that thrives in the digestive tract mucus of the human body. An omnipresent organism existing in more than 50% of the global populace, H. pylori may be the cause of serious upper gastrointestinal disorders, namely gastric cancer, peptic ulcer disease, & chronic gastritis. Analysts state that Aalta Bio’s new MAb thus, would prove to be immensely beneficial to combat the recurrence of this bacterium, which as per the CDC, is reportedly the principal cause of more than 80% of gastric ulcers and over 90% of duodenal ulcers.

The CEO of Aalto Bio Reagents, Philip Noone, is apparently rather pleased with the new MAb, and has been quoted stating that the new MAb’s addition to the H. pylori segment may strengthen the company’s presence in this expansive domain. Indeed, he says, the firm already benefits from its well-established, native H. pylori antigen that is used to produce myriad IgA, IgM, and IgG ELISAs that have already made a place for themselves in the mainstream market.

If estimates are to be believed, global H. pylori market size has been anticipated to grow at a CAGR of more than 8% over 2017-2027, essentially on account of the rapidly increasing global geriatric population susceptible to myriad infectious diseases. In this regard, Aalta Bio’s MAb is certain to bring about a transformation in this domain, while simultaneously contributing toward the expansion of cell line development market, cite experts.